Pharma company Lupin Ltd today said it has received approval from the Drugs Controller General (India) (DCGI) to conduct Phase II clinical trials for the molecule LL-42 18 (Desoside-P).
The company received permission to continue Phase II clinical trials on the Psoriasis pure compound, LL-42 18, after DCGI found the clinical Phase I data of the molecule to be satisfactory.
Lupin informed the Bombay Stock Exchange that it intends to begin clinical trials at 5-6 centres immediately.
'We are delighted that our Phase I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward and look forward to meeting this otherwise unmet market need,' Company Chairman Desh Bandhu Gupta said.
LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.
The company said it also has three other new chemical entities in various stages of clinical trials.